FOXM1 PEPTIDE AND MEDICINAL AGENT COMPRISING THE SAME

摘要

An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below:
(A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3;(B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3,

wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and

wherein the peptide shows cytotoxic (killer) T cell-inducing activity.

主权项

1. An isolated peptide of (A) or (B) below:
(A) a peptide of less than 15 amino acids comprising the amino acid sequence of SEQ ID NO: 2; (B) a peptide of less than 15 amino acids which comprises the amino acid sequence of any one of SEQ ID NO: 2, in which one or two amino acid(s) are substituted, deleted, inserted, and/or added, wherein the peptide shows cytotoxic (killer) T cell-inducing activity.